KRAS and pancreatic neoplasm: Firstly, we used three KRAS mutant pancreatic cancer cell lines (Patu-8988T, MiaPaca2 and T3M4) and one normal human epithelial pancreatic cell line (HPNE), and compared basal gemcitabine sensitivity using IC50 analysis, assessing cell proliferation after a 72 h treatment.